vs
Cadre Holdings, Inc.（CDRE）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Cadre Holdings, Inc.的季度营收约是Sanara MedTech Inc.的6.1倍（$167.2M vs $27.5M）。Cadre Holdings, Inc.净利率更高（7.0% vs -5.9%，领先12.9%）。Sanara MedTech Inc.同比增速更快（4.6% vs -5.0%）。Cadre Holdings, Inc.自由现金流更多（$18.0M vs $3.9M）。过去两年Sanara MedTech Inc.的营收复合增速更高（21.8% vs 10.1%）
Cadre Holdings, Inc.是美国金融科技企业，面向个人及机构客户提供房地产投资项目直投渠道，覆盖纽约等地的商业地产。公司打造的投资平台支持投资者自主选择参与的具体交易项目，且投资门槛远低于全额收购物业所需资金，让不动产投资变得更接近股票交易，获得财经媒体的广泛认可。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
CDRE vs SMTI — 直观对比
营收规模更大
CDRE
是对方的6.1倍
$27.5M
营收增速更快
SMTI
高出9.6%
-5.0%
净利率更高
CDRE
高出12.9%
-5.9%
自由现金流更多
CDRE
多$14.1M
$3.9M
两年增速更快
SMTI
近两年复合增速
10.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $167.2M | $27.5M |
| 净利润 | $11.7M | $-1.6M |
| 毛利率 | 43.4% | 93.2% |
| 营业利润率 | 12.2% | 23.5% |
| 净利率 | 7.0% | -5.9% |
| 营收同比 | -5.0% | 4.6% |
| 净利润同比 | -9.6% | 5.3% |
| 每股收益（稀释后） | $0.22 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDRESMTI
| Q4 25 | $167.2M | $27.5M | ||
| Q3 25 | $155.9M | $26.3M | ||
| Q2 25 | $157.1M | $25.8M | ||
| Q1 25 | $130.1M | $23.4M | ||
| Q4 24 | $176.0M | $26.3M | ||
| Q3 24 | $109.4M | $21.7M | ||
| Q2 24 | $144.3M | $20.2M | ||
| Q1 24 | $137.9M | $18.5M |
净利润CDRESMTI
| Q4 25 | $11.7M | $-1.6M | ||
| Q3 25 | $10.9M | $-30.4M | ||
| Q2 25 | $12.2M | $-2.0M | ||
| Q1 25 | $9.2M | $-3.5M | ||
| Q4 24 | $13.0M | $-1.7M | ||
| Q3 24 | $3.7M | $-2.9M | ||
| Q2 24 | $12.6M | $-3.5M | ||
| Q1 24 | $6.9M | $-1.8M |
毛利率CDRESMTI
| Q4 25 | 43.4% | 93.2% | ||
| Q3 25 | 42.7% | 92.9% | ||
| Q2 25 | 40.9% | 92.5% | ||
| Q1 25 | 43.1% | 92.2% | ||
| Q4 24 | 43.9% | 91.4% | ||
| Q3 24 | 36.6% | 90.8% | ||
| Q2 24 | 40.6% | 90.0% | ||
| Q1 24 | 41.8% | 89.8% |
营业利润率CDRESMTI
| Q4 25 | 12.2% | 23.5% | ||
| Q3 25 | 12.0% | 11.2% | ||
| Q2 25 | 9.3% | -0.1% | ||
| Q1 25 | 10.4% | -8.9% | ||
| Q4 24 | 16.7% | 18.6% | ||
| Q3 24 | 5.0% | 3.6% | ||
| Q2 24 | 13.8% | -14.3% | ||
| Q1 24 | 8.7% | -8.3% |
净利率CDRESMTI
| Q4 25 | 7.0% | -5.9% | ||
| Q3 25 | 7.0% | -115.5% | ||
| Q2 25 | 7.8% | -7.8% | ||
| Q1 25 | 7.1% | -15.1% | ||
| Q4 24 | 7.4% | -6.5% | ||
| Q3 24 | 3.3% | -13.2% | ||
| Q2 24 | 8.7% | -17.4% | ||
| Q1 24 | 5.0% | -9.5% |
每股收益（稀释后）CDRESMTI
| Q4 25 | $0.22 | $-0.32 | ||
| Q3 25 | $0.27 | $-3.40 | ||
| Q2 25 | $0.30 | $-0.23 | ||
| Q1 25 | $0.23 | $-0.41 | ||
| Q4 24 | $0.32 | $-0.18 | ||
| Q3 24 | $0.09 | $-0.34 | ||
| Q2 24 | $0.31 | $-0.41 | ||
| Q1 24 | $0.18 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $122.9M | $16.6M |
| 总债务越低越好 | — | $46.0M |
| 股东权益账面价值 | $317.8M | $5.9M |
| 总资产 | $770.0M | $72.9M |
| 负债/权益比越低杠杆越低 | — | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资CDRESMTI
| Q4 25 | $122.9M | $16.6M | ||
| Q3 25 | $150.9M | $14.9M | ||
| Q2 25 | $137.5M | $17.0M | ||
| Q1 25 | $133.4M | $20.7M | ||
| Q4 24 | $124.9M | $15.9M | ||
| Q3 24 | $93.0M | $16.3M | ||
| Q2 24 | $105.9M | $6.2M | ||
| Q1 24 | $87.1M | $2.8M |
总债务CDRESMTI
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
股东权益CDRESMTI
| Q4 25 | $317.8M | $5.9M | ||
| Q3 25 | $340.4M | $6.1M | ||
| Q2 25 | $332.5M | $35.4M | ||
| Q1 25 | $317.6M | $36.7M | ||
| Q4 24 | $311.5M | $39.4M | ||
| Q3 24 | $300.3M | $39.8M | ||
| Q2 24 | $299.4M | $41.7M | ||
| Q1 24 | $270.7M | $43.3M |
总资产CDRESMTI
| Q4 25 | $770.0M | $72.9M | ||
| Q3 25 | $792.1M | $71.1M | ||
| Q2 25 | $794.4M | $98.8M | ||
| Q1 25 | $656.3M | $96.4M | ||
| Q4 24 | $652.7M | $88.1M | ||
| Q3 24 | $616.6M | $88.5M | ||
| Q2 24 | $620.6M | $73.4M | ||
| Q1 24 | $599.4M | $70.9M |
负债/权益比CDRESMTI
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $3.9M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $3.9M |
| 自由现金流率自由现金流/营收 | 10.7% | 14.0% |
| 资本支出强度资本支出/营收 | 2.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.81× | — |
| 过去12个月自由现金流最近4个季度 | $56.8M | $2.2M |
8季度趋势，按日历期对齐
经营现金流CDRESMTI
| Q4 25 | $21.3M | $3.9M | ||
| Q3 25 | $22.5M | $2.2M | ||
| Q2 25 | $2.6M | $2.7M | ||
| Q1 25 | $17.4M | $-2.0M | ||
| Q4 24 | $23.7M | $932.0K | ||
| Q3 24 | $-5.2M | $2.1M | ||
| Q2 24 | $11.1M | $-1.4M | ||
| Q1 24 | $2.1M | $-1.6M |
自由现金流CDRESMTI
| Q4 25 | $18.0M | $3.9M | ||
| Q3 25 | $21.6M | $1.1M | ||
| Q2 25 | $1.2M | $902.7K | ||
| Q1 25 | $16.1M | $-3.7M | ||
| Q4 24 | $22.4M | $859.9K | ||
| Q3 24 | $-6.2M | $2.0M | ||
| Q2 24 | $9.1M | $-1.5M | ||
| Q1 24 | $794.0K | $-1.7M |
自由现金流率CDRESMTI
| Q4 25 | 10.7% | 14.0% | ||
| Q3 25 | 13.9% | 4.2% | ||
| Q2 25 | 0.7% | 3.5% | ||
| Q1 25 | 12.4% | -15.9% | ||
| Q4 24 | 12.7% | 3.3% | ||
| Q3 24 | -5.7% | 9.4% | ||
| Q2 24 | 6.3% | -7.3% | ||
| Q1 24 | 0.6% | -9.0% |
资本支出强度CDRESMTI
| Q4 25 | 2.0% | 0.3% | ||
| Q3 25 | 0.5% | 4.0% | ||
| Q2 25 | 0.9% | 6.8% | ||
| Q1 25 | 1.0% | 7.4% | ||
| Q4 24 | 0.7% | 0.3% | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.3% | ||
| Q1 24 | 1.0% | 0.4% |
现金转化率CDRESMTI
| Q4 25 | 1.81× | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 0.21× | — | ||
| Q1 25 | 1.88× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | -1.43× | — | ||
| Q2 24 | 0.89× | — | ||
| Q1 24 | 0.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDRE
| U.s.state And Local Agencies | $72.7M | 43% |
| Other | $48.6M | 29% |
| U.s.Federal Agencies | $31.6M | 19% |
| Commercial | $12.0M | 7% |
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
